Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

GSK slimming further as sales fall on Advair competition

GlaxoSmithKline says its three-part deal to sell and combine assets with Novartis should wrap up in the first half of next year and is now turning its attention to selling off some of its established drug portfolio, a category which took a 40% sales hit in the U.S. and 10% in the EU in Q2.

China allows trial of investigators of GSK sex-tape scandal to go public

China has abruptly changed course on its plans to prosecute private investigator Peter Humphrey and his wife Yu Yingzeng in a closed trial. Now Humphrey and Yu, who were arrested last summer as part of China's investigation of bribery charges involving GlaxoSmithKline, will be tried in a public proceeding.

Bioinformatics skills help Codexis strike $25M deal with GSK

Codexis strengthened its ties to small-molecule synthesis this week through a deal with GlaxoSmithKline. The agreement will see GSK pay $6 million upfront and more in milestones to license the platform.

GlaxoSmithKline's melanoma combo beats Roche's Zelboraf in Phase III

GlaxoSmithKline is touting stellar Phase III results for an in-development combo therapy for melanoma, saying its treatment beat out Roche's Zelboraf in overall survival and led independent advisers to recommend an early end for the study.

New scrutiny for GlaxoSmithKline after news of 2001 bribery-related housecleaning in China

GlaxoSmithKline's bribery woes in China apparently go back a bit further than the $489 million scandal that broke last summer. The U.K. company has acknowledged that it fired about 30 staffers in its China vaccines business in 2001 after turning up evidence of corruption.

Novartis' soon-to-be-Glaxo's vaccine unit sees mounting losses, diving sales in Q2

After years of waiting for a turnaround in its vaccines unit, it looks like Novartis may have sold it off at the right time. The Basel-based drugmaker Thursday reported stepped-up operating losses and flagging sales for the division, much of which will be on its way to former rival GlaxoSmithKline when the companies' $7.1 billion deal closes next year.

As Glaxo begins 2014-15 flu vaccine shipments, manufacturing questions linger

While GlaxoSmithKline is eyeing a strong performance from Fluarix Quadrivalent in its sophomore year, it may have to rely on Fluarix more than it would like if it doesn't make peace with regulators over quality issues at its FluLaval plant.

GlaxoSmithKline and Theravance eye Phase III for another COPD contender

The blockbuster duo of GlaxoSmithKline and Theravance are pushing a new respiratory combo therapy into late-stage study, pooling the active ingredients from its last two approved COPD treatments to create a once-daily inhaler.

Former GSK China employees fight back after 'illegal' firings

As part of GlaxoSmithKline's post-bribery-scandal efforts to clean up its marketing act, it has laid off workers whose business expenses didn't quite add up. But unfairly so, according to a trio of plaintiffs.

Ex-China staffers sue GSK for 'illegal' termination amid bribery scandal

As part of GlaxoSmithKline's post-bribery-scandal crackdown in China, it has tossed out employees whose expenses were "not compliant with company regulation." But now, three former employees say they were fired illegally--and they're fighting back in court.